drugset / Trial / NCT01234779
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
RandomizedParallel-groupDouble-blindTreatment
Summary
This randomized, double-blind, placebo- and active-controlled, parallel group study will evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute exacerbation of schizophrenia. Patients will be randomized to receive either RO4917838 10 mg or RO4917838 30 mg or olanzapine 15 mg or placebo orally daily for 4 weeks as inpatients, with a 4-week follow-up period.
Timeline
- Start
- 2011-02
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Olanzapine | Small molecule | 15 mg | Oral |
| Subject | bitopertin | Small molecule | 10 mg | Oral |
| Subject | bitopertin | Small molecule | 30 mg | Oral |